Endocrine Aspects of Prostate Cancer

  • K. Griffiths
  • M. E. Harper
  • C. L. Eaton
  • A. Turkes
  • W. B. Peeling
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Prostatic cancer in the year 2000 will be at the forefront of medical problems affecting the male population of the world. There is now a considerable amount of evidence to indicate that cancer of the prostate gland is, or is quickly becoming, the most commonly diagnosed cancer in men in the western world. The incidence rate appears to be consistently rising and, interestingly, the mortality rate for the black population of the United States of America is double that of the white people. It is becoming very evident that prostatic disease, both benign prostatic hyperplasia (BPH) as well as cancer, has become a serious health-care problem, particularly when considered in relation to the ever increasing proportion of the population in the more developed countries that is over the age of 65 years.

Keywords

Prostatic Cancer Androgen Receptor Proliferate Cell Nuclear Antigen Estramustine Phosphate Atypical Adenomatous Hyperplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Turkes AO, Peeling WB and Griffiths K: Treatment of patients with advanced cancer of the prostate: Phase III trial, Zoladex against castration; a study of the British Prostate Group. J Steroid Biochem 1987(27):543–549PubMedCrossRefGoogle Scholar
  2. 2.
    Harper ME, Glynne-Jones E, Goddard L, Wilson DW, Matenhelia SS, Conn IG, Peeling WB and Griffiths K: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. The Prostate 1992 (20):243–253PubMedCrossRefGoogle Scholar
  3. 3.
    Rowland AJ, Harper ME, Wilson DW and Griffiths K: The effect of an anti-membrane antibody-methotrxate conjugate on the human prostatic tumour line PC3. Br J Cancer 1990 (61):702–708PubMedCrossRefGoogle Scholar
  4. 4.
    Simpson HW, Mutch F, Halberg F, Griffiths K and Wilson DW: Bimodal age-frequency distribution of epitheliosis in cancer mastectomies. Relevance to preneoplasia. Cancer 1982 (50):2417–2422PubMedCrossRefGoogle Scholar
  5. 5.
    Griffiths K, Davies P, Eaton CL, Harper ME, Turkes A and Peeling WB: Endocrine factors in the initiation, diagnosis and treatment of prostatic cancer. In: Voigt KD and Knabbe C (eds) Endocrine Dependent Tumors. Raven Press Ltd, New York 1991 pp 83–130Google Scholar
  6. 6.
    Bishop JM: Cellular oncogenes and retroviruses. Ann Rev Biochem 1983 (52):301–354PubMedCrossRefGoogle Scholar
  7. 7.
    Weinberg RA: Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989 (49):3713–3721PubMedGoogle Scholar
  8. 8.
    Folkman, J: Toward an understanding of angio-genesis: search and discovery. Perspect in Biol and Med 1985 (29):10–36Google Scholar
  9. 9.
    Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991 (64):327–336PubMedCrossRefGoogle Scholar
  10. 10.
    Green S and Chambon P: Nuclear receptors enhance our understanding of transcription regulation. Trends Genet 1988 (4):309–314PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • K. Griffiths
    • 1
  • M. E. Harper
    • 1
  • C. L. Eaton
    • 1
  • A. Turkes
    • 1
  • W. B. Peeling
    • 2
  1. 1.Tenovus Cancer Research CentreUniversity of Wales College of MedicineCardiffUK
  2. 2.Department of UrologySt Woolos HospitalNewportUK

Personalised recommendations